Company: TELO
Filing Date: 2025-02-04
Form Type: 10-K
Source: 0001493152-25-004872
Chunk: 473

Company: Telomir Pharmaceuticals, Inc.
Filing Date: 2025-02-04
Form: 10-K
Item: Item 1A
Chunk 473
---
. from Loyola University
Stritch School of Medicine, completed his radiology residency at Loyola University Medical Center, and his musculoskeletal radiology
fellowship at the University of Arizona Health Sciences Center – Tucson. Dr. Del Giudice is licensed to practice medicine in Florida
and Ohio. Dr. Del Giudice also serves as a director of MIRA Pharmaceuticals, Inc. (Nasdaq:MIRA)

56

Craig
Eagle, MD joined our company as a director in November 2022. He has also served as a director of MyMD since April 16, 2021. Dr.
Eagle is currently the Chief Medical Officer of Guardant Health, Inc. since 2021. Previously, Dr. Eagle was Vice President of Oncology
for Genentech, where he oversaw the medical programs across Genentech’s oncology portfolio. Prior to his current role, Dr. Eagle
worked in several positions at Pfizer from 2009 to 2019, including as the oncology business lead in the United Kingdom and Canada, the
global lead for Oncology Strategic Alliances and Partnerships based in New York, and as the head of the Oncology Therapeutic Area Global
Medical and Outcomes Group, including the U.S. oncology medical business. Through his multiple roles at Pfizer, Dr. Eagle delivered significant
business growth and was involved in multiple strategic acquisitions and divestitures. In addition, while at Pfizer, Dr. Eagle oversaw
extensive oncology clinical trial programs, multiple regulatory and payer approvals across Pfizer’s oncology portfolio, health
outcomes assessments and scientific collaborations with key global research organizations like the National Cancer Institute (NCI), and
the European Organization for Research and Treatment of Cancer (EORTC), and led worldwide development of several compounds including
celecoxib, aromasin, irinotecan, dalteparin and ozagomicin. Dr. Eagle currently serves as a member of the board of directors and chair
of the Science and Policy Committee of Pierian Biosciences, a privately held life sciences company. Dr. Eagle attended Medical School
at the University of New South Wales, Sydney, Australia and received his general internist training at Royal North Shore Hospital in
Sydney. He completed his hemato-oncology and laboratory hematology training at Royal Prince Alfred Hospital in Sydney and was granted
Fellowship in the Royal Australasian College of Physicians (FRACP) and the Royal College